A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.
Latest Information Update: 18 Sep 2019
At a glance
- Drugs Tarafenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Kwang Dong Pharmaceutical
- 09 Apr 2013 Status changed from recruiting to completed.
- 09 Apr 2013 Primary endpoint 'Reduction in micturition-rate' has been met.
- 24 Nov 2011 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea; KCT0000207).